Anti-transthyretin antibodies

Patent metadata

Field	Value
Publication number	US-11267877-B2
Application number	US-201816753307-A
Country	US
Kind code	B2
Filing date	Oct 5, 2018
Priority date	Oct 6, 2017
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, and for monitoring the efficacy of TTR therapies, among other applications.

First claim

What is claimed is:

1. An isolated monoclonal antibody that binds human transthyretin (TTR), comprising three heavy chain CDRs of SEQ ID NO: 81 and three light chain CDRs of SEQ ID NO: 87.

2. The antibody of claim 1 , wherein the three heavy chain CDRs are as defined by Kabat/Chothia Composite (SEQ ID NOs: 5, 7, and 9) and the three light chain CDRs are as defined by Kabat/Chothia Composite (SEQ ID NOs: 11, 13, and 15).

3. The antibody of claim 1 that has a human IgG1 isotype, or that has a human IgG2 or IgG4 isotype.

4. The antibody of claim 1 that is an intact antibody.

5. The antibody of claim 1 that is a binding fragment.

6. A pharmaceutical composition comprising a first antibody of claim 1 , a second antibody, and a pharmaceutically acceptable carrier,
wherein the second antibody is selected from the group consisting of:
an antibody comprising three heavy chain CDRs of SEQ ID NOs:75-77 and three light chain CDRs of SEQ ID NOs:78-80;
an antibody comprising three heavy chain CDRs of SEQ ID NOs:39-41 and three light chain CDRs of SEQ ID NOs:42-44;
an antibody comprising three heavy chain CDRs of SEQ ID NOs:46-48 and three light chain CDRs of SEQ ID NOs:49-51;
an antibody comprising three heavy chain CDRs of SEQ ID NOs:52-54 and three light chain CDRs of SEQ ID NOs:55-57;
an antibody comprising three heavy chain CDRs of SEQ ID NO:58 and three light chain CDRs of SEQ ID NO:59;
an antibody comprising three heavy chain CDRs of SEQ ID NOs:60-62 and three light chain CDRs of SEQ ID NOs:63-65; and
an antibody comprising three heavy chain CDRs of SEQ ID NOs:66-68 and three light chain CDRs of SEQ ID NOs:69-71.

7. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

8. A nucleic acid encoding the heavy chain and/or light chain of an antibody as described in claim 1 .

9. A recombinant expression vector comprising a nucleic acid of claim 8 .

10. A host cell transformed with the recombinant expression vector of claim 9 .

11. A method of treating a transthyretin-mediated amyloidosis in a subject, comprising administering to the subject an effective regime of the antibody of claim 1 .

12. The method of claim 11 , wherein the transthyretin-mediated amyloidosis is associated with a condition selected from any of cardiomyopathy or hypertrophy, familial amyloid polyneuropathy, central nervous system selective amyloidosis (CNSA), senile systemic amyloidosis, senile cardiac amyloidosis, spinal stenosis, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, age related macular degeneration, and a ligament or tendon disorder.

13. The method of claim 11 , wherein the transthyretin-mediated amyloidosis is associated with amyloid accumulation in the heart, peripheral nervous system, autonomic nervous system, kidneys, eyes, abdominal fat, or gastrointestinal tract of the subject.

14. The method of claim 11 , wherein the transthyretin-mediated amyloidosis is a familial transthyretin amyloidosis or a sporadic transthyretin amyloidosis.

15. The method of claim 14 , wherein the familial transthyretin amyloidosis is familial amyloid cardiomyopathy (FAC), familial amyloid polyneuropathy (FAP), or central nervous system selective amyloidosis (CNSA).

16. The method of claim 15 , wherein the sporadic transthyretin amyloidosis is senile systemic amyloidosis (SSA) or senile cardiac amyloidosis (SCA).

17. A method of diagnosing a transthyretin-mediated amyloidosis in a subject, comprising contacting a biological sample from the subject with an effective amount of the antibody of claim 1 .

18. A method of detecting the presence or absence of transthyretin deposits in a subject, comprising contacting a biological sample from the subject suspected of comprising the amyloid accumulation with an effective amount of the antibody of claim 1 .

19. The antibody of claim 1 that is a chimeric, humanized, or veneered antibody.

20. The antibody of claim 19 , wherein the antibody is a humanized antibody.

21. The humanized antibody of claim 20 , wherein the mature light chain variable region is fused to a light chain constant region and the mature heavy chain variable region is fused to a heavy chain constant region.

22. The humanized antibody of claim 21 , wherein the heavy chain constant region is a mutant form of a natural human heavy chain constant region which has reduced binding to a Fcγ receptor relative to the natural human heavy chain constant region.

23. The humanized antibody of claim 21 , wherein the mature heavy chain variable region is fused to a heavy chain constant region having the sequence of SEQ ID NO:22 with or without the C-terminal lysine and/or the mature light chain variable region is fused to a light chain constant region having the sequence of SEQ ID NO:24.

24. The humanized antibody of claim 20 comprising a humanized mature heavy chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs:85-86 and a humanized mature light chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 91-92.

25. The humanized antibody of claim 24 wherein the mature heavy chain variable region has an amino acid sequence of any of SEQ ID NO: 85-86 and the mature light chain variable region has an amino acid sequence of any one of SEQ ID NO: 91-92.

26. The humanized antibody of claim 24 wherein at least one of the following positions is occupied by the amino acid as specified: H37 is occupied by V or A, H45 is occupied by L or Q, H47 is occupied by L or W, H48 is occupied by V or I, H49 is occupied by A or G, and H94 is occupied by S or R.

27. The humanized antibody of claim 26 , provided positions H37, H45, H47, H48, H49, and H94 in the VH region are occupied by A, Q, W, I, G, and R, respectively.

28. The humanized antibody of claim 24 wherein at least one of the following positions is occupied by the amino acid as specified: L2 is occupied by I or V and L45 is occupied by Q or R.

29. The humanized antibody of claim 28 , provided positions L2 and L45 in the VL region are occupied by V and R, respectively.

30. The humanized antibody of claim 20 , wherein the CDRs are of a definition selected from the group consisting of Kabat, Chothia, Kabat/Chothia Composite, AbM and Contact definitions.

31. The humanized antibody of claim 30 , wherein the humanized mature heavy chain variable region comprises three Kabat/Chothia Composite heavy chain CDRs of SEQ ID NOs: 5, 7, and 9 and the humanized mature light chain variable region comprises the three Kabat/Chothia Composite light chain CDRs of SEQ ID NOs: 11, 13, and 15.

32. The humanized antibody of claim 30 wherein the humanized mature heavy chain variable region comprises three Kabat heavy chain CDRs of SEQ ID NO:93, SEQ ID NO:7, and SEQ ID NO:9 and the humanized mature light chain variable region comprises three Kabat light chain CDRs of SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:15.

33. The humanized antibody of claim 30 wherein the humanized mature heavy chain variable region comprises three Chothia heavy chain CDRs of SEQ ID NO:94, SEQ ID NO:96, and SEQ ID NO:9 and the humanized mature light chain variable region comprises three Chothia light chain CDRs of SEQ ID NO:11, SEQ ID NO:13, and SEQ ID NO:15.

Assignees

• Prothena Biosciences Ltd

Inventors

• Salmans Joshua Reginald
• Alexander Svetlana
• Barbour Robin
• Higaki Jeffrey N
• Nijjar Tarlochan S

Classifications

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61K31/603

  having further aromatic rings, e.g. diflunisal · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title